Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.

Human gene therapy - 1 Feb 2018

Zhang Wei-Wei, Li Longjiang, Li Dinggang, Liu Jiliang, Li Xiuqin, Li Wei, Xu Xiaolong, Zhang Michael J, Chandler Lois A, Lin Hong, Hu Aiguo, Xu Wei, Lam Dominic Man-Kit

Abstract excerpt

Gendicine (recombinant human p53 adenovirus), developed by Shenzhen SiBiono GeneTech Co. Ltd., was approved in 2003 by the China Food and Drug Administration (CFDA) as a first-in-class gene therapy product to treat head and neck cancer, and entered the commercial market in 2004. Gendicine is a biological therapy that is delivered via minimally invasive intratumoral injection, as well as by intracavity or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Genetic Vectors

Share to Mutation

Share to Neoplasms

Share to Recombination, Genetic

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 29338444
DOI: 10.1089/hum.2017.218

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.PMID 29338444Read ↗

Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncologySemantic proximity Read ↗

Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China.Semantic proximity Read ↗

Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumorsSemantic proximity Read ↗

Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of CancersSemantic proximity Read ↗

Advances in adenovirus-mediated p53 cancer gene therapySemantic proximity Read ↗

INGN 201 (Advexin): adenoviral p53 gene therapy for cancer.Semantic proximity Read ↗

Head and neck cancer: Response to p53‐based therapeuticsSemantic proximity Read ↗

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectivesSemantic proximity Read ↗

Adenovirus p53 gene therapySemantic proximity Read ↗

The Role of p53 in Nanoparticle-Based Therapy for CancerSemantic proximity Read ↗

Completed Clinical Trials of p53 Gene Therapy in Cancer: A ClinicalTrials.gov-Based AnalysisSemantic proximity Read ↗

[Detection of p53 gene change and serum antibody level in phase II clinical trial of ad p53 gene therapy].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.